|
MabCampath® (alemtuzumab) Reimbursement/ Coverage
The Genzyme Oncology Patient Reimbursement Assistance Program will help your patients in finding available sources of reimbursement for all Genzyme Oncology Products.
Please contact your Genzyme Oncology representative, or call 1-888-760-6454 if you have any questions or which to receive patient information and referral forms.
Genzyme Oncology Patient Reimbursement Assistance Program
Patient Enrolment Form
MabCampath® (alemtuzumab) 
DIN 02290960
MabCampath® is an eligible benefit through some private insurance plans, and also through some provincial and federal drug programs. Additionally MabCampath® is also under review for funding in some provinces. The sidebar menu allows you to access specific information on coverage of MabCampath® by private insurance plans, the individual provincial drug benefit/ provincial cancer agency programs and through the federal drug plans. Information includes coverage/ reimbursement criteria and guidelines, special authorization forms, instructions and other resources. Click on the plan or program name to access.
Indication
MabCampath® (alemtuzumab) is indicated for the treatment of patients with previously untreated progressive B-CLL. The effectiveness of MabCampath® as a single agent for the treatment of patients with previously untreated B-CLL is based on progression-free survival (PFS), complete response (CR) and overall response (OR) rates. Currently no data are available that demonstrate an increased overall survival with MabCampath®. MabCampath® (alemtuzumab) is also indicated for the treatment of B-CLL patients who have been treated with alkylating agents and who have failed fludarabine therapy. Physicians should carefully weigh the benefits and risks of treatment with MabCampath®, taking into consideration the prognostic characteristics of B-CLL patients such as Rai Stage before initiating treatment.
Geriatrics: Comparisons of AUC in previously treated B-CLL patients 65 years or older (n=6) versus previously treated B-CLL patients less than 65 years (n=15) suggested that no dose adjustments are necessary for age.
Treatment with MabCampath® is contraindicated in patients who have active infections, patients with underlying immunodeficiency (e.g., seropositive for HIV), patients who have or have had progressive multifocal leukoencephalopathy (PML), patients who have known Type I hypersensitivity or anaphylactic reactions to MabCampath® (alemtuzumab) or to any one of its components and patients with active secondary malignancies.
Serious Warnings and PrecautionsMabCampath ® should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. - Hematologic: Serious and, in rare instances fatal, pancytopenia/ marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia have occurred in patients receiving MabCampath® therapy. Single doses of MabCampath® greater than 30 mg or cumulative doses greater than 90 mg per week should not be administered because these doses are associated with a higher incidence of pancytopenia.
- Infusion Reactions: MabCampath® can result in serious, and in some instances fatal, infusion reactions. Patients should be carefully monitored during infusions and MabCampath® withheld for Grade 3 or 4 infusion reactions if indicated. Gradual escalation to the recommended maintenance dose is required at the initiation of therapy and after interruption of therapy for seven or more days.
- Infections, Opportunistic Infections: Serious, sometimes fatal, bacterial, viral, fungal, and protozoan infections have been reported in patients receiving MabCampath® therapy. Patients should be monitored for signs or symptoms of any infection. Prophylaxis directed against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections has been shown to decrease, but not eliminate, the occurrence of these infections. Anti-viral prophylaxis is strongly recommended.
- Progressive Multifocal Leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) has been reported in patients with B-CLL with or without treatment with MabCampath®. The frequency of PML in B-CLL patients treated with MabCampath® is no greater than the background frequency. Patients should be monitored for any new sign or symptom that may be suggestive of PML. MabCampath® dosing should be withheld immediately at the first sign or symptom suggestive of PML.
Because of the potential of transfusion associated Graft versus Host Disease (TAGVHD), it is recommended that patients who have been treated with MabCampath® should receive irradiated blood products.
Routinely monitor patients for CMV infection during MabCampath® treatment and for at least 2 months following completion of treatment. Withhold MabCampath® for serious infections and during antiviral treatment for CMV infection or confirmed CMV viremia. Initiate therapeutic ganciclovir (or equivalent) for CMV infection or confirmed CMV viremia.
Patients who have recently received MabCampath®, should not be immunized with live viral vaccines, due to their immunosuppression.
The most common adverse reactions with MabCampath® are: infusion reactions (pyrexia, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), infections (CMV viremia, CMV infection, other infections), gastrointestinal symptoms (nausea, emesis, abdominal pain), and neurological symptoms (insomnia, anxiety, headache), fatigue and hypertension. The most common serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/ infections.
Please refer to Product Monograph for complete Warnings and Precautions and Adverse Reactions.
Resources for Healthcare Professionals and Your Patients
MabCampath® Product Monograph.
Cancer Care Ontario, Program in Evidence-Based Care
Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia: A Clinical Practice Guideline.
This link will take you to the document on the Cancer Care Ontario web site. Click here
BC Cancer Agency
Chemotherapy Protocol, ULYALEM: Treatment of Fludarabine-Refractory B-Chronic Lymphocytic Leukemia (B-CLL) and T-Prolymphocytic Leukemia (T-PLL) with Alemtuzumab
Chemotherapy Protocols, Lymphoma & Myeloma (BCCA Web Site)
National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines - Non-Hodgkin's Lymphomas V.3.2007
This link will take you to the document on the NCCN web site. See page 5 for CLL/SLL. Click here
®MabCampath is a registered trademark, used under license by Genzyme Corporation.
|
.gif)
